Ascendis Pharma A/S (NASDAQ:ASND) Given New $352.00 Price Target at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by TD Cowen from $341.00 to $352.00 in a research note issued to investors on Friday, Marketbeat reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, October 13th. Citigroup reduced their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a report on Monday, October 26th. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Canaccord Genuity Group upped their price target on shares of Ascendis Pharma A/S from $268.00 to $274.00 and gave the company a “hold” rating in a report on Friday. Finally, Barclays lowered their price target on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average target price of $313.52.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $275.39 on Friday. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15. The company’s 50 day moving average is $242.67 and its 200 day moving average is $239.83. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a market cap of $17.18 billion, a PE ratio of 18.00 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. The business had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the company. Empowered Funds LLC increased its holdings in shares of Ascendis Pharma A/S by 0.5% during the 3rd quarter. Empowered Funds LLC now owns 188,229 shares of the biotechnology company’s stock valued at $42,884,000 after purchasing an additional 958 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Ascendis Pharma A/S by 2.6% in the third quarter. State Board of Administration of Florida Retirement System now owns 34,235 shares of the biotechnology company’s stock valued at $7,800,000 after purchasing an additional 852 shares during the period. First Trust Advisors LP grew its holdings in Ascendis Pharma A/S by 435.8% in the third quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company’s stock valued at $19,807,000 after purchasing an additional 70,714 shares during the period. Allianz SE grew its holdings in Ascendis Pharma A/S by 219.4% in the third quarter. Allianz SE now owns 16,215 shares of the biotechnology company’s stock valued at $3,694,000 after purchasing an additional 11,138 shares during the period. Finally, Advisors Asset Management Inc. purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $6,075,000.

More Ascendis Pharma A/S News

Investors following ASND have been watching these news items:

• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.